159 related articles for article (PubMed ID: 36991262)
21. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
[TBL] [Abstract][Full Text] [Related]
23. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract][Full Text] [Related]
24. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
25. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
[TBL] [Abstract][Full Text] [Related]
26. IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma.
Xu C; Bai Y; An Z; Hu Y; Zhang C; Zhong X
Mol Ther Oncolytics; 2022 Mar; 24():443-451. PubMed ID: 35141400
[TBL] [Abstract][Full Text] [Related]
27. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
28. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
29. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
30. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Zhu H; You Y; Shen Z; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
[TBL] [Abstract][Full Text] [Related]
31. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
32. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Hombach AA; Rappl G; Abken H
Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
[TBL] [Abstract][Full Text] [Related]
33. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
Stock S; Fertig L; Gottschlich A; Dörr J; Märkl F; Majed L; Menkhoff VD; Grünmeier R; Rejeski K; Cordas Dos Santos DM; Theurich S; von Bergwelt-Baildon M; Endres S; Subklewe M; Kobold S
Cancer Immunol Immunother; 2024 Apr; 73(6):100. PubMed ID: 38630291
[TBL] [Abstract][Full Text] [Related]
34. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
Yin Y; Rodriguez JL; Li N; Thokala R; Nasrallah MP; Hu L; Zhang L; Zhang JV; Logun MT; Kainth D; Haddad L; Zhao Y; Wu T; Johns EX; Long Y; Liang H; Qi J; Zhang X; Binder ZA; Lin Z; O'Rourke DM
Mol Ther; 2022 Jul; 30(7):2537-2553. PubMed ID: 35570396
[TBL] [Abstract][Full Text] [Related]
35. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
36. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.
Wang D; Aguilar B; Starr R; Alizadeh D; Brito A; Sarkissian A; Ostberg JR; Forman SJ; Brown CE
JCI Insight; 2018 May; 3(10):. PubMed ID: 29769444
[TBL] [Abstract][Full Text] [Related]
39. The IgG4 hinge with CD28 transmembrane domain improves V
Li N; Quan A; Li D; Pan J; Ren H; Hoeltzel G; de Val N; Ashworth D; Ni W; Zhou J; Mackay S; Hewitt SM; Cachau R; Ho M
Nat Commun; 2023 Apr; 14(1):1986. PubMed ID: 37031249
[TBL] [Abstract][Full Text] [Related]
40. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.
Barish ME; Weng L; Awabdeh D; Zhai Y; Starr R; D'Apuzzo M; Rockne RC; Li H; Badie B; Forman SJ; Brown CE
Neoplasia; 2022 Aug; 30():100801. PubMed ID: 35550513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]